News

Celgene has acquired Gloucester for $340m in cash plus up to an additional $300m payable upon achievement of certain future regulatory milestones. The transaction brings to Celgene Istodax

Following receipt of the notice from the FDA that Impax’s ANDA had been accepted for filing, Impax has notified the New Drug Application holder and patent owners of

The company claims that Bacitracin Ophthalmic ointment, USP is the first product transfer to be completed. It is anticipated that the transfer of Erythromycin Ophthalmic ointment is expected

Currently, over 143 patients are enrolled in the CTCL study. The study is a multinational, non-randomised, open-label, single-arm trial, evaluating 200mg once-daily oral Forodesine treatment. Reportedly, the study

The result was published in the January issue of Mayo Clinic Women’s HealthSource. It also posts safety concerns and the maximum dose to be taken. The reported adverse

Tarceva is a once-a-day pill that targets the EGFR pathway. It is designed to inhibit the tyrosine kinase activity of the EGFR signaling pathway inside the cancer cell.

The original SCD-HeFT study has proved the effectiveness of ICD therapy over placebo or Amiodarone (a medication used to treat irregular heartbeats) for a specific population of patients.

In November 2009, the US, several states, and Omnicare entered into a $98m settlement agreement that, among other things, resolved Omnicare’s civil liability under the False Claims Act

Under the agreement, Chemtura will source BA-59PTM, DE-83RTM, Firemaster 2100, n-propyl bromide and sodium bromide from Albemarle. Additionally, Albemarle is assigning its brine interests in Chemtura’s West Brine